12 Jun PROBODY Technology Allows Chemo To Be Used Just At Tumor Site, Limiting Side Effects
MedicalResearch.com Interview with:
Alex Spira, MD, PhD, FACP
Virginia Cancer Specialists and
Chair of the US Oncology Research Executive Committee
MedicalResearch.com: What is the background for this study? Would you explain what the conjugate consists of and what types of cancer it may target? What are the main findings?
Response: The concept of the CX072 and CX2029 studies is that they use what’s called a probody molecule that gets broken down only at the tumor site. This is completely novel in that it helps diminish toxicity by not having less systemic absorption. In the case of CX2029, this target was previously undruggable, meaning the systemic toxicity was too high. By limiting it to activity at the tumor, that is significantly abated.
MedicalResearch.com: What are the main findings?
Response: The study is interesting because, especially in the case of CX2029, expansion cohorts are opening where activity has been seen. It’s also unique because you can apply this technology to virtually any antibody, meaning it’s a chance to diminish toxicity and improve efficacy.
Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal J. Lakhani, Hirva Mamdani, Jordi Rodon Ahnert, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, and Alexander I. Spira
Journal of Clinical Oncology 2020 38:15_suppl, 3502-3502
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.